Evidence map›Paper›PMID 42796309›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study.

Hakan Taban, Sercan Aksoy, Deniz Can Güven, Burak Yasin Aktaş, Feride Yılmaz, Ferit Aslan, Mustafa Erman

Abstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hakan TabanMedical Oncology Clinic, Medical Park Ankara Hospital, 06680 Ankara, Turkey.ORCID 0000-0002-2004-7741
Sercan AksoyDepartment of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey.ORCID 0000-0003-4984-1049
Deniz Can GüvenDepartment of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey.ORCID 0000-0002-6924-9467
Burak Yasin AktaşDepartment of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey.ORCID 0000-0001-5460-4895
Feride YılmazMedical Oncology Clinic, Samsun Education and Research Hospital, 55090 Samsun, Turkey.ORCID 0000-0001-5848-3381
Ferit AslanMedical Oncology Clinic, Medical Park Ankara Hospital, 06680 Ankara, Turkey.ORCID 0000-0002-9153-6921
Mustafa ErmanDepartment of Preventive Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey.ORCID 0000-0001-5884-4669

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantAgedEtoposideHumansMaleMiddle AgedPhenotypePrognosisRetrospective StudiesTreatment OutcomeEtoposideaggressive-variant prostate cancermetastatic castration-resistant prostate cancerneuroendocrine prostate cancerplatinum-based chemotherapyprognostic factors

Identifiers

PMID42796309
PMCPMC13609250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.